Stockscreener 앱 받기
4.63
4.99%
0.22
Aldeyra Therapeutics Inc 주식(ALDX)의 최신 뉴스
Following a 4.3% decline over last year, recent gains may please Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) institutional owners - simplywall.st
Behavioral Patterns of ALDX and Institutional Flows - Stock Traders Daily
Support Test: Does Aldeyra Therapeutics Inc have a sustainable dividend2025 EndofYear Setup & Weekly High Potential Stock Alerts - baoquankhu1.vn
Aldeyra Therapeutics (ALDX) Leads in Earnings Momentum - GuruFocus
Analysis Recap: Is Aldeyra Therapeutics Inc stock trending bullish2025 Momentum Check & Community Trade Idea Sharing Platform - baoquankhu1.vn
Aldeyra drops as FDA delays review of marketing application for lead drug - MSN
Will Aldeyra Therapeutics Inc. stock maintain momentum in 2025Weekly Profit Report & Risk Controlled Daily Trade Plans - Улправда
Market Trends: Will Aldeyra Therapeutics Inc. stock maintain momentum in 2025Portfolio Risk Report & Fast Gain Stock Tips - Bộ Nội Vụ
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Passes Below 50 Day Moving AverageTime to Sell? - MarketBeat
Can Aldeyra Therapeutics Inc. stock rebound after recent weaknessDay Trade & Daily Entry Point Trade Alerts - Улправда
Why Aldeyra Therapeutics Inc. stock attracts high net worth investors2025 Big Picture & Weekly Momentum Stock Picks - Улправда
Growth Value: Why Aldeyra Therapeutics Inc. stock attracts high net worth investorsEarnings Risk Summary & Detailed Earnings Play Strategies - Улправда
News | postregister.comAldeyra Therapeutics, Inc.Common Stock (Nasdaq:ALDX) Detailed Stock Data - FinancialContent
(ALDX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Aldeyra Therapeutics announces chief development officer resignation - MSN
What to keep an eye on in 2026 - Eyes On Eyecare
Aldeyra Therapeutics Chief Development Officer Stephen Machatha to Resign - marketscreener.com
Aldeyra Therapeutics (NASDAQ:ALDX) Shares Cross Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Aldeyra Therapeutics chief development officer to step down by March 2026 - Investing.com South Africa
Aldeyra Therapeutics Announces Chief Development Officer Resignation - TipRanks
Aldeyra Therapeutics Announces Resignation of Chief Development Officer - TradingView — Track All Markets
Aldeyra Therapeutics: Reproxalap’s March 2026 FDA Decision Is The Defining Catalyst - Seeking Alpha
Why is Aldeyra Therapeutics stock surging after FDA delayed its dry eye drug decision? - MSN
Why (ALDX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Aldeyra Therapeutics (NASDAQ:ALDX) Stock Crosses Above Fifty Day Moving AverageShould You Sell? - MarketBeat
Aldeyra Therapeutics, Inc.'s (NASDAQ:ALDX) Institutional Shareholders Had a Great Week as One-year Returns Increased After a 24% Gain Last Week - 富途牛牛
Aldeyra Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance
Can SAL Steel Limited Maintain Growth Without Diluting ShareholdersLong-Term Investment Plans & Small Investment Capital Gains - earlytimes.in
What dividend safety score for Aldeyra Therapeutics Inc. stockMarket Trend Summary & Reliable Trade Execution Plans - DonanımHaber
What Wall Street predicts for Aldeyra Therapeutics Inc. stock priceWeekly Stock Summary & Real-Time Market Sentiment Reports - Улправда
Will Aldeyra Therapeutics Inc. stock benefit from infrastructure spendingSwing Trade & Fast Gaining Stock Strategy Reports - Улправда
ALDX LEGAL NEWS: BFA Law Announces that Aldeyra Therapeutics, Inc. is being InvestigatedContact the Firm if You Lost Money - 28/22 News
Aldeyra Therapeutics Earnings Notes - Trefis
Aldeyra Therapeutics Sees Unusually Large Options Volume (NASDAQ:ALDX) - Defense World
Aldeyra Therapeutics Target of Unusually Large Options Trading (NASDAQ:ALDX) - MarketBeat
Buy Rating for Aldeyra Therapeutics: Confidence in Reproxalap’s Approval and Financial Upside - TipRanks
Why Is Aldeyra Therapeutics Stock Surging After FDA Delayed Its Dry Eye Drug Decision? - Asianet Newsable
Aldeyra Therapeutics (NASDAQ: ALDX) updates on FDA review of reproxalap - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Aldeyra stock surges as FDA delays dry eye drug decision | Tap to know more | Inshorts - Inshorts
ALDX: FDA extends reproxalap NDA review by 90 days after requiring field trial CSR submission - TradingView — Track All Markets
FDA Extends Review Timeline For Aldeyra's Dry Eye Disease Drug - Sahm
Aldeyra Therapeutics (ALDX) Faces FDA Review Delay for Reproxala - GuruFocus
Why Is Aldeyra Therapeutics Stock Falling Tuesday?Aldeyra Therapeutics (NASDAQ:ALDX) - Benzinga
Transcript : Aldeyra Therapeutics, Inc.Special Call - marketscreener.com
Aldeyra stock drops on FDA delay for lead drug (ALDX:NASDAQ) - Seeking Alpha
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Aldeyra Therapeutics Faces FDA PDUFA Date Extension - TipRanks
Aldeyra Says FDA Extends Action Date for Potential Dry Eye Disease Treatment; Shares Down Pre-Bell - marketscreener.com
4.73%
0.92%
자본화:
|
볼륨(24시간):